Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia

• Main Authors: Zhengqi Wang (Author), Tian Mi (Author), Heath L. Bradley (Author), Jonathan Metts (Author), Himalee Sabnis (Author), Wandi Zhu (Author), Jack Arbiser (Author), Kevin D. Bunting (Author)
• Format: Book
• Published: MDPI AG, 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Acute myeloid leukemia (AML) is a heterogeneous disease with a high relapse rate. Cytokine receptor targeted therapies are therapeutically attractive but are subject to resistance-conferring mutations. Likewise, targeting downstream signaling pathways has been difficult. Recent success in the develo...